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ABSTRACT 
Acyclovir has low bioavailability mainly due to low solubility. This study aimed to formulate an optimized acyclovir (ACV) 
nanoemulsion gel for the slow, variable and incomplete oral drug absorption in patient suffering from herpes simplex viral infection. 
The dispersion solubility of acyclovir was studied in various oils, surfactants and co-surfactants and by constructing pseudo phase 
ternary diagram nanoemulsion area was identified. The optimized formulations of nanoemulsions were subjected to thermodynamic 
stability tests. After stability study, stable formulation was characterized for droplet size, pH determination, centrifugation, % drug 
content in nanoemulsion, Zeta Potential and Vesicle size measurement and than nanoemulsion gel were prepared and characterized 
for spreadability, measurement of viscosity, drug content, In-vitro diffusion, in-vitro release data. Span 40 was selected as surfactant, 
PEG 400 as co surfactant and castor oil as oil component based on solubility study. The in vitro drug release from acyclovir 
nanoemulsion gel was found to be considerably higher in comparison to that of the pure drug. The in-vitro diffusion of 
nanoemulsion gel was significantly good. Based on this study, it can be concluded the solubility and permeability of acyclovir can be 
increased by formulating into nanoemulsion gel. 
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INTRODUCTION 
Acyclovir (ACV) is a guanosine antiviral drug and is 
one of the antiviral drugs most commonly used for 
treatment of herpes simplex virus infection, as well as 
varicella zoster (chickenpox) and herpes zoster 
(shingles). Topical application of ACV is limited by low 
transdermal penetration and poor solubility in water. 
Many strategies have been used to improve the 
therapeutic efficacy of ACV, including chemical 
modification, liposomes and nanoparticles
1, 2
. ACV is 
slightly soluble in water, with solubility ranging from 
1.2 to 1.6 mg/mL at room temperature
3, 4
 has relatively 
low oral bioavailability (10%–30%), has a short plasma 
half-life and is absorbed from the gastrointestinal tract 
via passive diffusion and by transporters but its 
absorption is slow, variable and incomplete
5
. 
The term nanoemulsion (NE) refers to a type of emul-
sion with a droplet size in its internal phase ranging from 
5 nm to 200 nm and forms spontaneously with a 
transparent appearance. It is stabilized by a strong 
interfacial film of surfactant and cosurfactant/cosolvent 
molecules. Techniques such as microfluidization, high 
pressure homogenization
6
, emulsion inversion point
7
 and 
sonication
8
 have been utilized in preparation of NEs. 
NEs have been reported to successfully deliver a wide 
variety of therapeutic agents. Nanoemulsions are also 
referred to as miniemulsions, ultrafine emulsions and 
submicron emulsions. Phase behaviour studies have 
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shown that the size of the droplets is governed by the 
surfactant phase structure (bicontinuous microemulsion 
or lamellar) at the inversion point induced by either 
temperature or composition. The capacity of 
nanoemulsions to dissolve large quantities of 
hydrophobics, along with their mutual compatibility and 
ability to protect the drugs from hydrolysis and 
enzymatic degradation
9
. The objective of this study was 
to develop and characterize nanoemulsion gel of 
acyclovir for increasing solubility and permeability 
across the biological membrane to improve the 
bioavailability, dosing frequency and enhance patient 
compliance. 
MATERIALS AND METHODS 
Acyclovir was obtained as a gift sample from Macleods 
pharmaceuticals, Mumbai.  Span 40, PEG 400 and castor 
oil were purchased from S. D. Fine Chem. Ltd., 
Mumbai. All other surfactant and co surfactant were 
purchased from Hi Media, Mumbai. Double distilled 
water was prepared freshly and used whenever required. 
All other chemicals used in this study including those 
stated were of analytical reagent (A.R.) grade. 
Solubility studies 
Solubility determination in the various oils, surfactants 
and co-surfactants for formulating nanoemulsion drug 
delivery system. The solubility of the drug in different 
oils is an essential step for the nanoemulsion 
formulation. So before starting the phase diagram one 
must have to select the oil, surfactant and co-surfactant 
in which the drug shows maximum solubility, to be in 
the desired solubility range, which is essential for the 
formulation of nanoemulsion drug delivery system. The 
solubility of ACV was determined by dissolving an 
excess amount of the drug in 2 ml of each liquid 
separately. The mixtures were shaken at 25°C±0.5°C for 
48 hours in a water bath. After reaching equilibrium, the 
mixtures were centrifuged at 3,000 rpm for 15 minutes 
using a centrifuge REMI laboratory, Mumbai. The 
supernatant was diluted with ethanol and the 
concentration of ACV was quantified 
spectrophotometrically at 242 nm. Each experiment was 
performed in triplicate. 
Experimental design for formulation of 
nanoemulsion 
Bearing in mind the efficiency of the mixture 
experimental design for the optimization of the NE, the 
pseudo-ternary phase diagrams was utilized to study and 
statistically optimize the effects of three components in 
8 runs in randomized order. Surfactant and co-surfactant 
(Smix) in each group were mixed in different volume 
ratios Span 40: PEG 400 (1:1, 1:2, 1:3, 3:1, 2:1) and the 
stock of 100 mL of each groups was prepared. These 
(Smix) ratios were chosen in increasing concentration of 
cosurfactant with respect to surfactant and increasing 
concentration of surfactant with respect to cosurfactant 
for detailed study of the phase diagrams for the 
nanoemulsions formation. Construction of pseudo-
ternary phase diagrams different ratio of oil and Smix 
was taken castor oil: Span 40 + PEG 400 (1:2, 2:1, 3:1) 
and prepared the nanoemulsion. The different conc. of 
oil and mixture of surfactant and cosurfactant were taken 
as 0.5:9.5, 0.5:9, 2.8, 3.7, 4:6, 5:5, 6:4 and 7:3. Ternary 
mixtures were formed in this ratio and quantity of water 
forming transparent solution was plotted in the pseudo-
ternary phase diagram.  
Formulation of acyclovir nanoemulsion 
according to mixture design 
After the development of phase diagram, eight 
formulations each containing 10 mg ACV, were pre-
pared with varying concentrations of oil mixture, 
surfactant mixture and cosurfactant mixture (Table 1). 
For any mixture, the sum of the three components 
always equals 100%. 
 
Table 1 Formula composition of prototype formulations 
Oil: Smix Formulation code Oil (mg) Surfactant(mg) Co-surfactants(mg) 
0.5:9.5 F1 0.050 0.470 0.470 
0.5:9 F2 0.056 0.467 0.467 
2.8 F3 0.198 0.396 0.396 
3.7 F4 0.298 0.346 0.346 
4:6 F5 0.396 0.297 0.297 
5:5 F6 0.496 0.247 0.247 
6:4 F7 0.594 0.198 0.198 
7:3 F8 0.694 0.148 0.148 
 
Evaluation of nanoemulsion formulations 
pH Determination 
The pH of each formulation was found before and after 
dilution by using pH meter results given in Table 3. 
Thermodynamic stability studies 
The obtained NE formulations were subjected to various 
thermodynamic stability studies in order to assess their 
phase separation and/or stability
10
. The prepared NE 
formulations was subjected to centrifugation at 3,000 
rpm for 30 minutes and to repeated cycles of heating and 
cooling (three freeze-thaw cycles) at -20°C and +25°C to 
measure their thermodynamic stability. The resulting 
formulations were then tested for phase separation, 
creaming, or cracking. The globule size was measured to 
ensure NE stability. 
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Centrifugation 
This parameter characterized to check the physical 
stability of formulation. The nanoemulsion system was 
centrifuged at 5000 rpm for 10 minutes to determine 
whether the system shows signs of creaming or phase 
separation. The system was observed visually for 
appearance. 
Determination of % drug content in nanoemulsion 
The mixture (Nanoemulsion) was centrifuged at 1000 
rpm for 15 min, 0.2 ml of supernatant was taken and 
diluted with 0.1 N HCL. Absorbance was measured at 
242nm by UV Spectrophotometer. Concentration of 
acyclovir was determined using standard curve equation 
and % drug content was calculated results given in Table 
4. 
Zeta potential and vesicle size measurement of 
optimized batch F3 
Zeta Potential of samples was measured by Zeta sizer. 
Samples were placed in clear disposable zeta cells and 
results were recorded results show in Fig. 1& 2 
Formulation development of nanoemulsion 
loaded gel 
Preparation of carbopol gel base: 0.5 g Carbopol 934 
was weighed and dispersed in water with mild stirring 
and allowed to swell for 24 hours to obtain 0.5% gel. 
Later 2 ml of glycerin was added to for gel consistency. 
Similarly 1 and 2% carbopol gels were prepared. 
Preparation of niosomes gels: Equivalent to 1g of 
nanoemulsion formulation was dissolved in 10ml of 
ethanol and centrifuged at 6000 rpm for 20 minutes to 
remove the unentrapped drug. The supernant was 
decanted and sediment was incorporated into the gel 
vehicle. 
The incorporation of the nanoemulsion into gels was 
achieved by slow mechanical mixing at 25 rpm for 10 
minutes. The optimized formulation was incorporated 
into three different gel concentration 0.5, 1 and 2% w/w 
Table 2. 
Table 2: Composition of different gel base 
Formulation Carbopol (%) 
F1 0.5 
F2 1.0 
F3 2.0 
 
Evaluation of nanoemulsion gel formulations 
Determination of pH 
Weighed 50 gm of gel formulation were transferred in 
10 ml of beaker and measured it by using the digital pH 
meter. pH of the topical gel formulation should be 
between 6-7 to treat the skin infections. 
Spreadability 
A modified apparatus suggested was used for 
determining spreadability. The spreadability was 
measured on the basis of slip and drag characteristics of 
the gels. The modified apparatus was fabricated and 
consisted of two glass slides, the lower one was fixed to 
a wooden plate and the upper one was attached by a 
hook to a balance. The spreadability was determined by 
using the formula: S=ml/t, where S, is spread ability, m 
is weight in the pan tied to upper slide and t is the time 
taken to travel a specific distance and l is the distance 
traveled. For the practical purpose the mass, length was 
kept constant and‘t’ was determined. The measurement 
of spreadability of each formulation was in triplicate and 
the average values are presented. 
Measurement of viscosity 
 The viscosity of gels was determined by using a Brook 
Field viscometer DV-II model. A T-Bar spindle in 
combination with a helipath stand was used to measure 
the viscosity and have accurate readings. The T-bar 
spindle (T95) was used for determining the viscosity of 
the gels. The factors like temperature, pressure and 
sample size etc. which affect the viscosity were 
maintained during the process. The helipath T- bar 
spindle was moved up and down giving viscosities at 
number of points along the path. The torque reading was 
always greater than 10%. Five readings taken over a 
period of 60 sec. were averaged to obtain the viscosity. 
Drug content 
Equivalent to 10mg (Acyclovir) of the prepared gel was 
mixed with 100 ml. of ethyl alcohol. Aliquots of 
different concentrations were prepared by suitable 
dilutions after filtering the stock solution and the 
absorbance was measured at 242 nm. Drug content was 
calculated by linear regression analysis of the calibration 
curve Table 5.  
In-vitro diffusion study 
An in-vitro drug release study was performed using 
modified Franz diffusion cell. Dialysis membrane (Hi 
Media, Molecular weight 5000 Daltons) was placed 
between receptor and donor compartments. 
Nanoemulsion gel equivalent to 5mg of drug was placed 
in the donor compartment and the receptor compartment 
was filled with phosphate buffer, pH 7.4 (24 ml). The 
diffusion cells were maintained at 37±0.5°C with stirring 
at 50 rpm throughout the experiment. At different time 
interval, 5 ml of aliquots were withdrawn from receiver 
compartment through side tube and analyzed for drug 
content by UV Visible spectrophotometer Table 6-9 & 
Fig. 3, 4.  
RESULTS AND DISCUSSION 
The preliminary study showed that acyclovir is white, 
crystalline, odorless powder. It is freely soluble in 
Ethanol, Methanol and 0.1 N HCL soluble in 
chloroform, slightly soluble in water. The melting point 
was in the range of 256-258
o
C which is in compliance 
with the standard value of 256
0
C as per Indian 
Pharmacopoeia. From the FT-IR data of the physical 
mixture it is clear that functionalities of drug have 
remained unchanged including intensities of the peak. 
On the basis of above study it was concluded that the 
solubility in the oils, surfactants and co surfactants like 
Span 40, Castor Oil, Oleic acid, PEG 400, Ethanol  was 
found to be soluble and Tween 20, Tween 80 and  
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Sunflower Oil was found to be Slightly soluble  for the 
nanoemulsion preparation of acyclovir. Different 
physicochemical properties of the selected oils were 
studied and were found to be favourable for 
nanoemulsion drug delivery system. The Vesicle size 
analysis of the optimized formulation F3 was done using 
particle size analyzer (Horiba).The mean Vesicle size 
was found to be 41.6nm. Zeta potential of the optimized 
formulation F3 was determined using particle size 
analyzer (Horiba). Zeta potential of optimized 
formulation was found to be -32.4mV. Drug content is 
most important in nanoemulsion formulation and the 
data found are satisfactory. It was found to be 
62.25±0.21 to 89.98±0.25% which shows the good 
capacity of formulation to hold the drug. Three Different 
carbopol gel base prepared for optimization (0.5%, 1.0% 
and 2%) and evaluated for pH, Spreadibility, Viscosity 
measurements and in vitro drug release studies. The 
spreadability was measured on the basis of slip and drag 
characteristics of the gels and was in the range of 20.75 
– 21.75gms. cm. /sec. In vitro drug release study of 
Optimized formulation was carried out using modified 
franz Diffusion cell. The optimized formulation F3 
showed the maximum 87.980% drug release in 8 hrs. 
Table 3: Results of pH of Acyclovir loaded 
nanoemulsion 
S. No. Formulation code pH* 
1 F1 6.81±0.02 
2 F2 6.92± 0.01 
3 F3 7.03±0.02 
4 F4 7.04±0.01 
5 F5 6.84±0.02 
6 F6 6.95±0.03 
7 F7 6.98±0.02 
8 F8 6.95±0.01 
             *Average of three determination
 
Table 4: Results of centrifugation and % drug content in nanoemulsion 
Formulation Code  Centrifugation % Drug Content in nanoemulsion* 
F1 Transparent  78.23±0.23 
F2 Transparent  75.58±0.15 
F3 Transparent  89.98±0.25 
F4 Transparent 82.25±0.25 
F5 Transparent 70.15±0.65 
F6 Transparent 65.56±0.32 
F7 Transparent 62.25±0.21 
F8 Transparent 65.56±0.28 
     *Average of three determination 
 
 
Figure 1 Result of zeta potential of optimized batch F3 (-32.4mV) 
 
Figure 2 Result of vesicle size of optimized batch F3 
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Table 5 Evaluation results of nanoemulsion gel formulations 
Code Drug content 
(%) 
pH Spreadability 
(Gm.cm/sec.) 
Viscosity 
(cps) 
F1 98.89± 0.021 7.0±0.021 20.75±0.075 6231±32 
F2 98.68 ± 0.021 7.2±0.040 21.08±0.042 6525±24 
F3 99.25 ±0.027 7.0±0.060 21.75±0.059 6758±25 
 
Table 6 In-vitro drug release data for formulation F1 
Time (h) 
Square Root 
of Time(h)
1/2
 
Log 
Time 
Cumulative*% 
Drug Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative % 
Drug Remaining 
0.5 0.707 -0.301 13.560 1.132 86.440 1.937 
1 1.000 0.000 32.560 1.513 67.440 1.829 
2 1.414 0.301 65.560 1.817 34.440 1.537 
4 2.000 0.602 75.580 1.878 24.420 1.388 
6 2.449 0.778 76.200 1.882 23.800 1.377 
8 2.828 0.903 76.210 1.882 23.790 1.376 
*Average of three readings 
Table 7 In-vitro drug release data for formulation F2 
Time 
(h) 
Square Root 
of Time(h)
1/2
 
Log 
Time 
Cumulative*% 
Drug Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative % 
Drug Remaining 
0.5 0.707 -0.301 20.250 1.306 79.750 1.902 
1 1.000 0.000 45.580 1.659 54.420 1.736 
2 1.414 0.301 68.890 1.838 31.110 1.493 
4 2.000 0.602 73.250 1.865 26.750 1.427 
6 2.449 0.778 73.560 1.867 26.440 1.422 
8 2.828 0.903 74.150 1.870 25.850 1.412 
*Average of three readings 
Table 8 In-vitro drug release data for formulation F3 
Time 
(h) 
Square Root 
of Time(h)
1/2
 
Log 
Time 
Cumulative*% 
Drug Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.707 -0.301 18.890 1.276 81.110 1.909 
1 1.000 0.000 38.890 1.590 61.110 1.786 
2 1.414 0.301 42.560 1.629 57.440 1.759 
4 2.000 0.602 54.650 1.738 45.350 1.657 
6 2.449 0.778 69.980 1.845 30.020 1.477 
8 2.828 0.903 87.980 1.944 12.020 1.080 
*Average of three readings 
 
 
Figure 3 Cumulative % drug released Vs time optimized formulation F3 
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Figure 4 Log cumulative % drug remaining Vs Time optimized formulation F3 
 
Table 9 Regression analysis data of optimized 
formulation 
Batch 
Zero Order First Order 
R² R² 
F3 0.952 0.923 
 
CONCLUSIONS 
This study demonstrates that a nanoemulsion 
formulation can be used to improve solubility, 
bioavailability of Acyclovir and overcome the dif-
ficulties associated with its use in the clinic. On 
analysing saturation solubility study result and pseudo 
ternary phase diagram, the oil, surfactant and co 
surfactant were selected. All the prepared formulations 
exhibited the nanoemulsion properties. The optimised 
formulation was evaluated for zeta potential, globule 
size analysis and stability study. The results suggest that 
the optimised formulation was stable and produced 
nanoemulsion. The in-vitro diffusion study of the 
formulation was higher as compared to pure drug, 
indicating that the prepared formulation is having higher 
solubility and permeability. Thus it can be concluded 
that nanoemulsion formulation can be used as a one of 
the formulation technique to enhance the bioavailability 
of the poorly soluble and permeable drugs. The present 
work aimed at developing a successful new topical 
formulation for the delivery of acyclovir was able to 
increase the efficacy of the currently available 
commercial products for the topical treatment of Herpes 
simplex virus infections. In this study, we got success in 
the development and evaluation of nanoemulsion. Based 
on higher drug release and lower surfactants 
concentration, higher solubility as well as higher 
bioavailability without variable absorption has been 
optimized as nanoemulsion formulation of acyclovir as 
oil, surfactants and co-surfactants. The above study 
leaves a future scope for refining technology which can 
further be used for preparation of various other nano 
systems in pharmaceutical products. 
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